logo
  

Myriad Genetics Targets To Be Profitable By Q4 - Quick Facts

Myriad Genetics, Inc. (MYGN) said the company is focused on returning to long-term organic growth and profitability, and expects to be profitable by fourth quarter of 2021. Beginning the current quarter, Myriad Genetics began to implement the second phase of its transformation plan.

Paul Diaz, CEO of Myriad Genetics, said: "We are now implementing enterprise capabilities including a new commercial model designed to improve the end-to-end customer experience together with focused research and technology initiatives, enhanced reimbursement, and revenue cycle management. This will provide a foundation for consistent, long-term growth and profitability."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors Co. (GM) said its second-quarter results were better than originally expected due to strong pricing and demand, record GM Financial results and improved near-term production from the pull forward of semiconductors from the third quarter. Based on first-half performance and expectations... PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast.
Follow RTT